#PGL1

[mleprae]

Leprosy and Tuberculosis have been referred gently as 'enemies with no medals' or 'wolves without teeth' in some papers I've seem, mostly because pathogenic bacteria are armed to the teeth to be able to deal with the immune system (Which is a power to be reckoned with.)

Pathogenic bacteria have toxins, specific receptors, ability to change shapes and to fight back in some cases, but Leprosy and Tuberculosis have nothing! And curiously enough, they have antigens that I crudely just refer to the bacterial 'siren song', Leprosy, being an intracelullar parasite cannot live only inside the body; it needs a cell to parasite. This antigen (PGL1), is kind of very fascinating to me, it mimics the chemicals used to summon immune cells, but specific ones, macrophages.

Macrophages are usually accompained by neutrophils as they kind keep each other in check, but in this case, leprosy has managed to be alter it's "call" to summon macrophages and macrophages only, as neutrophils are extremely agressive and would surely kill the bacteria. This siren call ensures leprosy has a host, by forcing it to destroy nerve cells (Schwann cells, specifically) where it resides, macrophages kill those nerve cells and eat the bacteria, where leprosy will do all its machinery to ensure its survival within that macrophage.

Asides from PGL1, leprosy has a lot of fun mechanisms to keep the immune system off its ass, it may not have claws but it's certainly a trickster of some sorts; a leprosy infection makes the body signal to the "wrong" cells, an example is that the body "wrongfully" tries to kill an extracelullar pathogen that does not exist (for the record, you do have a lot of defenses against intracelullar parasites btw), or when leprosy causes exhaustion in immune cells that were made to kill it, while most specialized cells become more and more aggressive as the stimuli to the pathogen becomes stronger, those who have been sensitized to leprosy become more and more "lethargic" as they get close to the target until they simply just... stop moving. There's a bunch of other ways leprosy just plays and tricks the body over and over for its survival, in a way I don't think I've ever seem in any other pathogen, which is certainly interesting

[littlenoobooplumbobs]

[not-poignant]

*calls research institute that only deals with rarest of endocrine cases and wonders if case is rare enough*

‘hi i have a genetic disease called the SDHD fault help me’ (heavily paraphrased)

‘oh that is very rare’

‘yes can you help me’

‘yes i think so can you get your doctor to give you an indefinite referral’

‘wait indefinite? oh, that’s right, it’s incurable’

‘yes, it is’

‘so my case is rare enough?’

‘yes, it is’

‘so i’ll probably see [desirable professor who has been recommended to me by desirable professor in Sydney but is extremely hard to see who only holds a clinic for two hours once a week and like at this point i’m pretty sure i’ll see Santa before i see him]?’

‘indeed it is his area and yes he is rarer than a unicorn but i think he’ll make an exception for your case.’

‘hey cool, i hope you have an awesome day thank you for helping me’

‘remember the referral needs to be indefinite.’

*hangs up*

my life is really weird at the moment.

[biogenericpublishers]

Head and Neck Paragangliomas: a Narrative Review by Diego Duminy-Luppi in Open Access Journal of Biogeneric Science and Research

Abstract

Head and neck neoplasms arising in the paraganglion tissue, comprising carotid body, vagal and temporal bone paragangliomas, account for a small part of extraadrenal paragangliomas. They represent, however, a challenging diagnosis that is often made quite late, appearing in some of the most complex anatomical areas with regards to surgery. Morbidity is also high, with often permanent cranial nerves damage or audio-vestibular injury, both by the tumours themselves or as a consequence of late surgery. Therefore, it is important for physicians to be informed as much as possible on this subject. Throughout a vast and thorough assessment of the state-of-the-art advances, as well as some previously published remarkable takes on the matter, this narrative review aims to cover what is needed to know about the epidemiology, pathophysiology, clinical manifestations, diagnosis and treatment of this otorhinolaryngological condition.

Keywords: Head and neck paraganglioma; Paraganglioma; Carotid body tumour; Vagal paraganglioma; Temporal bone paraganglioma; Jugulotympanic paraganglioma; Tympanomastoid paraganglioma; Otorhinolaryngology; Head and neck surgery; Narrative review.

Introduction

Paragangliomas are traditionally poorly defined in literature, as the definition varies depending on the sources. Some more specific designations have recently been revised, such as non-chromaffin (parasympathetic) and metameric (sympathetic), and the term chemodectoma is no longer used [1]. The 2017 WHO classification of tumours of the endocrine organs defines ‘extra-adrenal paraganglioma’ as both functional (catecholamine secreting) and non-functional, sympathetic or parasympathetic-derived neoplasms arising in extra-adrenal paraganglion tissue. Tumours with the same characteristics originated inside the adrenal glands would be referred to as pheochromocytomas [2], although in clinical practice the term ‘paraganglioma’ generally refers to head and neck tumours with these characteristics [3].

In this review, we will focus on the epidemiology, pathophysiology and clinical manifestations, as well as the diagnosis and treatment of three specific and most frequent types of head and neck paragangliomas (HN-PGLs), consisting of carotid body paragangliomas (CBPs), vagal paragangliomas (VPs) and temporal bone paraganglioma (TBPs), which includes both tympanomastoid (TMPs) and tympanojugular paragangliomas (TJPs). All of them are parasympathetic-derived paragangliomas, with CBP arising from the carotid body at the carotid bifurcation, VP arising mainly (but not only) from the nodose ganglion or inferior ganglion of the vagus nerve. TBPs arise from Jacobson’s nerve (i.e. the tympanic branch of CN IX), Arnold’s nerve (the auricular branch of CN X) and intravagal paraganglia inferior to foramen jugulare [4]. The apparition near the jugular bulb describes TJPs whereas the apparition in the tympanic or mastoid canaliculi describe TMPs [5]. They are indolent slow-growing tumours, mostly non-secreting, in a complex anatomical area [6].

The description of temporal bone paragangliomas has been highly inconsistent, coming from the lack of consensus terminology. The distinction between tympanomastoid and tympanojugular paraganglioma is often unavailable, mentioning ‘jugulotympanic paraganglioma’ as a sole entity, leaving unclear to the reader if the first is simply dismissed or included in the latter. Others have adopted the terminology ‘middle ear paraganglioma’, without specifying up to which extent nearby paragangliomas outside of the middle ear are considered. It is however consistent that glomus tympanicum and glomus jugulare are now both included and referred to as jugulotympanic paraganglioma. We will therefore mention as temporal bone paraganglioma all tympanomastoid paragangliomas, tympanojugular or jugulotympanic paragangliomas, temporal paragangliomas and jugular foramen paragangliomas, specifying the subtype only when the information refers to that specific subtype exclusively. Finally, ‘Head and neck’ is commonly defined as the anatomical area delimitated inferiorly by the clavicle and superiorly by the cranial vertex, and so does this review [7].

Methods

Resource publications for this narrative review were identified and selected through searches of PubMed and MEDLINE, using ‘cervical paraganglioma’, ‘paraganglioma’, ‘head and neck paraganglioma’, ‘vagal paraganglioma’, ‘carotid body paraganglioma’, ‘carotid body tumor’, ‘glomus jugulare’, ‘temporal bone paraganglioma’, ‘jugular foramen paraganglioma’, ‘middle ear paraganglioma’, ‘glomus tympanicum’ and ‘jugulotympanic paraganglioma’ as search terms. Studies selected for this review include the most recent advances in research until November 2019, they were published in high-impact, peer-reviewed journals, and showed results based on satisfactory numbers of study participants, covering a relevant population.

Epidemiology

The incidence of head and neck paragangliomas in the general population ranges from 1/30.000 to 1/100.000 per year. CBPs account for approximately 60% and TBPs account for 30% of them, leaving approximately 10% to VPs. Laryngeal paragangliomas are extremely rare, with less than 100 cases reported in literature. The remaining ones (non-head and neck) are mostly found in the abdomen region [8-11]. Only 10% of paragangliomas do not occur in the adrenal paraganglia and are thus not pheochromocytomas. Of these, 97% arise in non-head and neck locations [12].

60% of HN-PGLs are sporadic, although the remaining 40% are familial inherited cases associated with succinate dehydrogenase subunits mutations [10]. These familial cases are more likely to be bilateral and multiple (10-25% for CBPs and 20-40% for VPs, 30% for TBPs). Only 5% of cervical paragangliomas are catecholamines producers. Malignant behaviour isn’t predictable by clinical manifestations nor histology, although familial cases are associated with higher rates of malignancy than sporadic ones [8-10] The pathologies most associated with paragangliomas are type 2B Multiple Endocrine Neoplasia (MEN), type 1 neurofibromatosis and Von Hippel-Lindau syndrome [8,9].

CBPs appear between the 5th and 6th decade of life, show approximately 2:1 (female:male) gender predilection and are rarely bilateral if sporadic (5%) [10] VPs usually appear during the 5th decade of life, also show 2:1 (female:male) gender predilection and have higher chances of being bilateral/multifocal or metastatic than CBPs [10].

TBPs also usually appear between the 5th and 6th decades of life and exhibit female gender predilection with a female:male ratio of 3:1 [10,12] Jugular paragangliomas have their peak incidence in the 6th decade, and some authors point at a higher female to male ratio, as high as 4:1 or 6:1 [10,13,14]. Bimodal distribution of cases in tympanic paraganglioma has been mentioned, with a first smaller peak around the 4th decade [15] Malignant TBP cases are lower than in other HN-PGLs, and often associated to SDHB mutations. These range from 2-5% and come from the presence of metastases, as proliferative index Ki67 is almost always very low, around 1-2% [5,13,16] Interestingly, the incidence of cervical paragangliomas is higher in people living above 1.000m over the sea level, as encountered in a single cohort study, postulating a potential role of chronic hypoxia as a risk factor for CP [17].

Pathophysiology

Cervical paragangliomas are a rare group of tumours, originated from the chromaffin cells of the extra-adrenal paraganglionic system (derived originally from the crista neuralis), following the autonomous system chain over the head and neck. They are slowly growing and invasive to nearby structures, and consist of highly vascularized structures, getting its blood supply mainly from external carotid artery branches [18].

To elucidate the aetiology, it’s mandatory to separate between the familial and the sporadic cases. As mentioned before, the familial cases are related to succinate dehydrogenase (SDH) mutations in 4 locus: 11q23 (SDHD gene causing PGL1), 11q13 (PGL2), 1q21 (SDHC gene causing PGL3) and 1p36.1p35 (SDHB gene causing PGL4 [19] The inheritance pattern is autosomal dominant, with incomplete penetrance [20] SDH plays a role in the tricarboxylic acid cycle and oxidative phosphorylation located in the mitochondrial complex II. The mutation in SDH produces similar effects as chronic hypoxia in paraganglionic cells [21]. Mutations in SDHD and SDHB increase intracellular concentrations of hypoxia molecular mediators (HIF) and stimulate angiogenic genes (VEGF) that translate into an increased hyperplasic proliferation, causing the neoplasia [19]. SDHD mutations are more common in multifocal paragangliomas, including non-functional ones, whereas SDHB mutations are more associated with malignant behaviours [22]. Finally, the SDHA subunit mutation hasn’t been related with paragangliomas nor other tumours, but with the autosomal recessive young encephalopathy [23].

Macroscopic pathology of paragangliomas appears as well-circumscribed reddish-brown masses usually ranging from 2 to 6 centimetres at resection [6]. Rarely, the tumour can be pigmented [14] Jugular paragangliomas had an average size of 3.5 centimetres in a large retrospective study, whereas tympanic paragangliomas had considerably a smaller size with a mean of 0.7 centimetres [11].

Microscopic pathology shows a characteristic ‘Zellballen’ pattern composed by nests of neuroendocrine chief cells and peripheral glial-like sustentacular cells, surrounded by delicate vascular septae. Both types of cells are positive to immunochemistry staining with chromogranin, synaptophysin, neuron-specific enolase, CD56 and CD57 (chief cells) and S-100 (sustentacular cells). Antibodies against proteins encoded by recognised susceptibility genes (as previously mentioned) may also be used to establish an increased risk of germline mutations of these genes [24].

Clinical Manifestations

Clinical manifestations of head and neck paragangliomas are not so obvious, and whereas functional tumours are often suspected with the presentation of otherwise unexplained fluctuating or persistent specific symptoms such as headache, profuse sweating, palpitations, tachycardia, hypertension or anxiety, these only represent 1% of HN-PGLs, as even catecholamine secreting tumours often don’t reach high enough levels to produce symptoms [25,26] Most CBPs and VPs are thus non secreting at a clinically-significant level and grow on average at a rate of 0.83mm/year. Clinical manifestations mostly come from the compression or invasion of nearby structures, depending on the direction of the growth [6] TBPs also exhibit a similar slow growth, but often present in a symptomatic fashion. However, diagnosis is usually made after a considerable time, with patients waiting on average around 30 months before consultation [12,27].

The most common presentation of CBPs is that of an asymptomatic, pulsatile cervical mass, with a limited mobility in the cephalocaudal axis and good mobility in the lateral axis (classically referred to as Fontaine’s sign). In some cases, headache and syncope have also been reported as main complaints [28] Early detection through physical examination or self-detection may be challenging especially in obese patients. Bulging of the oropharyngeal wall is present in approximately 10% of tumours, originating hoarseness, dysphagia or foreign body sensation. Larger CBPs may cause vagal and hypoglossal palsy, and the compression of arteries may result in a noticeable bruit. Differential diagnosis of these masses includes carotid aneurysms and neurilemmomas [14].

VPs also present as painless cervical masses, and occasionally patients will show dysphagia and hoarseness. Oropharynx may be deviated following the occupation of parapharyngeal space. Cranial nerve (CN) dysfunction occurs more frequently than with CBPs, with preoperative weakness of CN X occurring in one third of patients [14,29]. In some cases, other CNs may be involved, such as CN IX, and although rare, the involvement of the sympathetic chain can cause Horner’s Syndrome. Also rare but of major importance, VPs may reach the skull base and extend intracranially (dumbbell-shaped tumour), or involve the jugular foramen and the atlas [6] Polymyalgia rheumatica is a described paraneoplastic syndrome associated with benign VP [30].

TBPs usually present as symptomatic tumours. Depending on their location and extension, symptoms may vary, as these appear based on the structure they alter by compression or erosion. Jugular paragangliomas will have higher rate of CN dysfunction, whereas tympanic paragangliomas will have significantly higher hearing symptoms. Both can however extend into the other’s anatomical area, ultimately behaving in a similar manner [11]. Most commonly reported symptoms are pulsatile tinnitus ranging from 60 to 80% of patients, and hearing loss, in 55 to 80% of patients [5,13-15,27] Conductive hearing loss is predominant, whereas neurosensorial hearing loss is less frequent and shows itself in extended tumours with vestibular involvement [13,27]. Aural fulness is also frequently reported, in up to 70% of patients [10,15] CN abnormalities are often present, in up to 40% of patients [5,16] These will show up in a clinical examination, or through a wide variety of symptoms such as dysphonia, dysphagia, dysarthria, tongue weakness, hoarseness and shoulder pain or weakness [12-15,31] Specifically, CN VII is affected in up to 39% of patients, CN IX and X in up to 40% of patients, and CN XI and XII in up to 30% of patients [5] Both Vernet syndrome (CN IX, X, XI abnormality) as well as Collet-Sicard syndrome (CN IX, X, XI, XII abnormality) have been described associated to TBPs, with the latter in up to 10% of jugular paragangliomas [13].

Some authors have considered the presence of a red, vascular middle-ear mass as pathognomonic of TBP, whereas others simply describe it as very common finding [5,14]. This mass can also be pulsatile [5,14,15] Other characteristic sings are Brown’s sign, described as a blanching of the lesion when pneumatic pressure is applied, revealing the vascular nature of the tumour, and the rising sun sign, presenting as an inferior semi-circular red-blue lesion behind the tympanic membrane [5,15] Rarer presentations may be vertigo (in up to 20%), otalgia (3%), otorrhagia (1.5-9.6%) and epistaxis (uncommon) [15,27]. Horner’s syndrome can also be seen [16].

CBPs’ malignancy rate is estimated between 5-10%. Pain, young age and rapid enlargement are the most predictive features. Although a retrospective cohort study reported a CBP with aggressive soft tissue invasion which affected the brachial plexus and cervical nerve roots, this is generally not accepted as a malignant CBP; malignancy requires the presence of regional or distant metastasis [11,29].

Metastatic CBP and VPs are rare but represent a challenging medical management. VPs are more like to become malignant and metastasize than CBPs [32] Described locations of metastatic CBP include peripheral lymph nodes or distant organs such as liver, bone, kidney, lungs, breast, pancreas, brain and thyroid gland [28,33]. Wang et al. mentioned what they believe to be the first case of CBP brain metastasis, with the particularity of having an endocrine activity [33]. The symptoms described were right limb weakness, dizziness, vomiting, hypertension and hyperglycaemia, resolving after the tumour extirpation. Needless to say, these are not the common rule. TBPs have even lower metastatic rates than CBPs, although some cases have been reported, especially in bone, lungs, lymph nodes and liver [5].

Differential diagnosis of CBPs include lymph nodes, which may or may not contain metastatic disease, mainly from other neuroendocrine tumours such as neuroendocrine carcinomas, Merkel cell carcinoma and medullary thyroid carcinoma. For VPs, differential diagnosis can be established with schwannomas, vascular tumours and parotid gland salivary tumours. When investigating a possible TBP, clinicians should keep in mind that meningioma, middle ear adenoma and haemangioma can present in a similar manner and share part of neuroendocrine markers [10]. Also, an inflammatory polyp, an aberrant internal carotid artery, an anatomic variation of the jugular bulb, a CN VII neuroma, an osteoma, a cholesteatoma or a cholesterol granuloma can be misdiagnosed as a TBP [27].

HN-PGLs may be hard to distinguish from atypical carcinoids, although some characteristics may help differentiate both: atypical carcinoids usually appear during the 6th-7th decade, metastasize frequently and primarily affect male patients (3:1 M:F), although they have the same clinical manifestations and ultimately require histologic analysis [10].

Diagnosis

As mentioned before, although clinically non-secreting, HN-PGLs may secrete catecholamines, which justifies why biochemical tests such as plasma free metanephrines or urinary fractionated metanephrines are recommended as initial investigation for paragangliomas [34]. Imaging studies should be performed once a positive biochemical test occurs, and include both contrast enhanced CT or Magnetic Resonance Imaging [34]. MRI is preferred in HN-PGLs, with a sensitivity of 90-95% (higher than CT), and it helps differentiate HN-PGLs from other tumours (such as Schwannoma, neurofibroma, carotid artery aneurism), and provides excellent details on extension and vascularization [4,34,35]. CBPs and TBPs show a characteristic salt-and-pepper image in contrast in T1 MRI, distinguishing areas with subacute haemorrhage and slow blood flow (‘salt’) from serpent-shaped flow voids (‘pepper’). Gadolinium intensively enhances these lesions, and T2 shows mildly and heterogeneously hyperintense, well defined mass [4-6,15,35].

If the invasion of the skull base is suspected, contrast enhanced CT provides excellent spatial resolution. MRI can be, and usually is, complementary to CT [6]. CBPs appear as a hypervascular mass that spreads between the internal and the external carotid arteries. However, it is usually located at the same level or below the carotid bifurcation, not above. Digital subtraction angiography may be performed to evaluate internal carotid infiltration or preoperatively if embolization is considered. The image is classically described as a ‘lyre sign’, and CBPs show a slow and prolonged blush. VPs can also appear as CBPs but they usually present behind the internal carotid artery and push the vessels in an anteromedial direction [4,6,29,35] Another characteristic is that they may separate the jugular vein from the carotid sheath [29].

In TBPs, radiologic studies are also paramount in order to further classify the tumour and determine the most appropriate approach to treatment. High-resolution CT scan with contrast is both sensitive and specific, usually showing localized irregular bone destruction at the jugular foramen, with sometimes enlargement of the latter. This pattern is traditionally described as ‘moth-eaten’ [4,5]. TBPs are a soft tissue mass, enhanced by contrast [35]. The erosion of the jugular plate suggests that the tumour is a jugular paraganglioma [36]. MRI is preferred and complementary to CT in order to precisely determine intracranial involvement, especially in those tumours reaching outside of the middle-ear [5,15,35]. Furthermore, MRI differentiates more accurately tympanic paragangliomas from jugular paragangliomas [5,12]. Angiography is not always performed, but can be considered in case of suspected invasion of the internal carotid artery, or the anterior vertebral artery [5]. Tympanic paragangliomas may grow inside the tympanic cavity without destroying the ossicles, but being attached to them [4,15].

Ultrasound, if performed, shows solid hypoechoic lesions [35]. Biopsy of suspected PGLs is contraindicated because of the high risk of bleeding [37]. For metastatic cases, 18FDG PET-CT is preferred because of its higher sensitivity when compared to other techniques, especially in SDHB-related PPGLs [34].

Treatment

There is widespread consensus in the literature with regards to surgery as the only available option for treatment. There is no effective medical therapy.

Shamblin et al [38]. suggested a classification in 1971 based on CBP tumour size and carotid artery invasion to assess resection possibilities:

Shamblin 1: Less frequent group, containing small size (<4cm) and well localized tumours, without invasion of major vessels and easily resectable.

Shamblin 2: Nearly 50% of the cases, containing of mid-size (>4cm) tumours, adhered to or partially surrounding major vessels. They compress the internal and external carotid artery but can be removed through a cautious subadventitial dissection.

Shamblin 3: More than 25% of the cases, containing big size tumours, invading carotids and nearby structures. In order to be completely removed, partial or total resection of these structures is needed.

The reasons to resect a cervical paraganglioma include the following: [39]

Some HN-PGLs could eventually become malignant, although it’s not possible to know before or after the surgery.

There is no true consensus on an optimal follow-up strategy.

No cases of spontaneous regression, even correcting hypoxemia, have been published.

The risk of vascular injury in experienced surgical teams intervening a Shamblin 1 tumour is minimal.

All tumours can become symptomatic.

The basic surgical technique consists of an incision over the anterior edge of sternocleidomastoid muscle. The deep anterior fascia is dissected in order to expose the common carotid artery, which is important for an early vascular control. The dissection plane then extends anteriorly until the carotid bifurcation. This way the subadventitial plane or ‘white line’ as described by Gordon-Taylor can be identified, which allows a fine separation of the tumour and the artery due to a relatively avascular plane [39,40].

The risk of an arterial injury during the resection increases with tumour size, but without a significative increase of brain ischaemic events. Adjacent CN lesions are one of the major risks during surgery, mainly accessory spinal nerve (XI), vagus nerve (X) and hypoglossal nerve (XII). Again, the risk increases with tumour size, but locating, isolating and carefully dissecting these structures prior to tumour resection decreases the risk. In vast tumours, where surgical resection could entail bigger morbidity, or in suboptimal basal patients, either because of age or because of concomitant pathologies, radiotherapy is indicated, with 45Gy in 25 fractions showing good results in/at stopping tumour progression at 5 and 10 years of follow-up (only 4 to 6% recurrence at 5 and 10 years respectively), but sometimes leaving an asymptomatic residual mass [39,41,42]. Regarding potential complications of radiotherapy, histologic examination has shown that chief cells are minimally affected by irradiation, although the distinctive vascular structure of the tumour is replaced by fibrous connective tissue, raising awareness over the appearance of malignant tumours such as fibrosarcoma [43-45]. 15% of patients who underwent radiotherapy suffered at least one complication, which include inflammation of the external auditory canal and middle ear, skin loss with bone exposure, osteoradionecrosis, cranial nerve neuropathies (specially hearing and taste loss, in <3%) and direct injury to brain tissue, among others. Additionally, it is worth mentioning that if radiotherapy fails, surgery will be more difficult [40,42,45-47] For CBPs, 14% of <5cm tumours extirpation entail CN disfunction as compared to 67% of >5cm tumours [12].

Another alternative worth mentioning is embolization, a technique consisting in introducing a catheter (generally through a percutaneous approach to the femoral vessels with Seldinger technique) to deploy coils in tumour’s vascularisation that will form a clot and interrupt blood flow, reducing blood loss and facilitating tumour resection. The procedure is usually undergone 48h before surgery to avoid intraoperatory inflammatory phenomena. There have been some controversial discussions regarding its efficacy, since it also entails some risks (distal embolization, necrosis, cerebral or ocular infarcts, etc.), so there is no real general consensus over the existing evidence [48].

For VPs, the same management options are generally considered. However, surgery isn’t supported by high levels of evidence, especially when compared to small CBPs, because an intervention almost always (93%) implies complete resection of the vague nerve which causes serious side effects such as unilateral vocal fold paralysis, pharyngeal plexus deficit, pharynx numbness and soft palate dysfunction, resulting in dysphagia and dysphonia among others, often worse than the tumour itself would cause. The typical approach is lateral, transcervical and preauricular, sometimes superiorly extended. Damage to other CNs is also possible, with numbers ranging from 21% to 39%. When compared to Radiotherapy (RT) and Stereotactic Radiosurgery (SRS), results are similar to surgery but with less damage to CN, postulating the option of an observation ± RT ± SRS as a reasonable alternative to surgery in selected patients [12]. A recent study has shown that immediate selective laryngeal reinnervation using the phrenic nerve and the ansa cervicalis as donor nerves after VP excision improves both dysphagia and dysphonia. [49] However, further evidence is needed to define management algorithms for VPs.

Regarding TBPs, the modified Fisch and Mattox classification is used to divide them based on their extension, which at the same time determines the optimal surgical approach (presented between brackets). Tympanomastoid paragangliomas, on the one hand, can be classified as class A, if they are confined to middle ear, and then further subdivided into A1 if the tumour margins are clearly visible on otoscopic examination (transcanal approach) or into A2 if margins are not visible on otoscopy (retroauricular-transcanal approach, glove finger flap technique). An emerging new technique, consisting of transcanal endoscopic minimally invasive surgery, has demonstrated feasibility and promising results among this class [50-52]. They can also be classified as class B if they are confined to the tympanomastoid cavity without bone destruction in the temporal infralabyrinthine compartment, and then further subdivided into B1 if they extend to the hypotympanum alone (canal wall up mastoidectomy with posterior tympanotomy), into B2 if they extend to the hypotympanum and the mastoid (canal wall up mastoidectomy with posterior tympanotomy and subfacial recess tympanotomy) or into B3 if they erode the carotid canal (subtotal petrosectomy with middle ear obliteration).(27) Major postoperative complications such as CN deficits are usually not expected, but minor complications such as postoperative conductive hearing loss may occur [53].

Tympanojugular paragangliomas, on the other hand, can be classified as class C if they extend beyond the tympanomastoid cavity, destroying bone of the infralabyrinthine and apical compartment of the temporal bone and involving the carotid canal, with further subdivisions C1-C4 depending on the degree of invasion (C1, tumours with limited involvement of the vertical portion of the carotid canal; C2, tumours invading the vertical portion of the carotid canal; C3, tumours with invasion of the horizontal portion of the carotid canal; C4, tumours reaching the anterior foramen lacerum). They can also be classified as class D if they extend intracranially (De1, tumours up to 2 cm dural displacement; De2, tumours with more than 2 cm dural displacement; Di1, tumours up to 2 cm intradural extension; Di2, tumours with more than 2 cm intradural extension; Di3, tumours with inoperable intradural extension) or as class V if they involve the vertebral artery (Ve, tumours involving its extradural portion; Vi, tumours involving its intradural portion) [5]. They are usually resected via an infratemporal approach, but C1, C2, De1, De2, Di1 and Di2 may demand a variant of the juxtacondylar approach [54] Because these tumours are adherent and occasionally CN IX-XII are involved, higher rates of CN deficits are anticipated for the postoperative outcome, and thus possibly requiring further surgical procedures attempting to correct them.(55,56) Di1 and Di2 tumours should be generally resected in a two-stage multidisciplinary procedure involving neurosurgeons, whereas in Di3 tumours palliative radiotherapy is advocated. Although some inconsistencies regarding Fisch classification and follow-up intervals among different studies must be taken into account, long-term success rate following surgical therapy of tympanojugular paragangliomas is 72-95% [54].

Conclusion

Paragangliomas are functional or non-functional, sympathetic or parasympathetic-derived neoplasms arising in extra-adrenal paraganglion tissue. Amongst these, HN-PGLs are mainly composed by CBPs, VPs, and TBPs. Some genetic associations have been described. Clinical manifestations are diverse although some signs and symptoms strongly suggest the diagnosis. Biochemical screening is the first complementary step when investigating a possible HN-PGL, followed, if positive, by the best available imaging technique, which usually narrows down the differential diagnosis. Surgical intervention, with or without previous embolization, is the best and only approved therapeutic option for CBPs and TBPs, whereas for VPs further evidence is needed to determine whether surgery with reinnervation or a combination of RT and SRS is the best therapeutic management strategy. For some tympanomastoid paragangliomas, endoscopic surgery is emerging with promising results.

More information regarding this Article visit: OAJBGSR

https://biogenericpublishers.com/pdf/JBGSR.MS.ID.00178.pdf https://biogenericpublishers.com/jbgsr-ms-id-00178-text/

[mleprae]

So, the way that your immune system works is that your innate immune system engages with a non specific quick response and your adaptative immune system engages with a slow but specific response

It may sound crazy, but the adaptative immune system has a specific weapon for EVERY PATHOGEN that EXISTS, HAS EXISTED and WILL EXIST, the way it works its honestly insane and is one of the most impressive feats of evolution

The way this works is that pathogens have "smells" called antigens, those antigens are specific to that species of bacteria so there's no species that share the same antigen/"smell" (usually)

Your adaptative system recognizes these antigens and prepares a weapon to deal with the bacteria that releases it, furthermore, it teaches the innate system to become aggressive to that smell, when the cell recognizes the bacteria that's releasing it, it tracks it down and kills it

Now the interesting thing about leprosy, is that it's smell/antigen (PGL1) does the opposite, the leprosy antigen actually triggers exhaustion and unresponsiveness in cells instead of aggression. Which one of the intriguing mechanisms it has to fight off the immune system, I don't think there's any other disease that does this as well which makes it even more fascinating!!

[mleprae]

another interesting about leprosy's antigen (aka PGL1) is that it is also a kind of a fucked up siren's call, though it likes to snack schwann cells it also likes macrophages which are, you know, the second largest immune cell

but its a smart little guy, because it can take over macrophages just fine, except that theyre usually accompanied by neutrophils who can kill leprosy, so PGL1 summons macrophages but suppresses neutrophils, ensuring a stable income of prey without the attention of other soldiers

[littlenoobooplumbobs]

[littlenoobooplumbobs]

[littlenoobooplumbobs]

Generation 1: ROSE PETAL

Traits: Ambitious, Loves the Outdoors, Vegetarian

Aspiration: Freelance Botanist

Berry Color: Red

Information: This is the founder of your legacy! From living their entire childhood in the smelly and loud city, they have decided to begin a new lifestyle in the countryside. They dream of running a farm to support the generations to come.

Rules:

Compete the freelance botanist aspiration

Reach level 10 of the gardener career

Have at least 2 children

Have 1 dog and 1 cat

Collect every base game plant

Care for at least 2 Cowplants throughout your life

Max friendship with at least 1 beehive

Reach level 10 of the gardening skill

Reach level 5 of the cooking skill

Reach level 5 of the parenting skill

Reach level 5 of the handiness skill

[littlenoobooplumbobs]

Tiger you should not drink that water...

[littlenoobooplumbobs]

This is her kitten Tiger.

[littlenoobooplumbobs]

[littlenoobooplumbobs]

[not-poignant]

Okay, an update on the Thelma and Louise ('Pia has two tumours named Thelma and Louise') situation!

If you're new to this situation, I have a thing called Hereditary PGL/PCC or PGL1 or the SDHD variant or gene fault. It is incurable. And it makes me grow tumours. It's also known as the paraganglioma/pheochromocytoma thingie, which are very rare endocrine tumours that are rather horrid and never benign, even if they're not metastatic. It's also known as  'you have para what?' and 'how do you pronounce that again?' and 'geez, I'm a doctor and I still have never heard of it' and 'is that cancer?' I currently have two paragangliomas. Both on the right hand side of my neck. One is a carotid body paraganglioma that sits nicely between the internal and external carotid arteries (this is bad for the arteries, they couldn’t save them the last time I had a carotid body paraganglioma on the left hand side). The other is a glomus vagale tumour that is growing in the vagus body of the vagus nerve, and this one is large enough to be pushing my arteries apart, and is a little too close to the jugular and the tympanic membrane and skull case. A hungry glomus vagale will happily eat the skull and penetrate into the brain, but...so far that’s not happened to me. *crosses fingers*

Right now, we are at the part of the Thelma and Louise movie where you're sort of in the gross part of the popcorn and the movie is dragging a bit and you're like 'we get it, it's a roadtrip, go off the cliff already.' I'm wishing I'd bought Maltesers along for the ride, and Glen's wondering why we came to see this dumbass movie in the first place.

Since the last time I updated, I've since had plasma metanephrines drawn again, and discovered I cannot actually do the 24 hour urine metanephrines test at all (because IBS). That's okay, plasma metanephrines will do.

Today I saw a high end Endocrinologist at Charles Gairdner hospital, in the Endocrinology (Endo) clinic. It was...a frustrating appointment.

Firstly, Endo don't handle the surgery, so he couldn't tell me anything regarding it, when it would be, what the side effects would be, or anything like that. (This prompted me to call my Vascular Surgeon’s office immediately afterwards and do the polite version of 'where the FUCK is my ENT surgeon already' at which the receptionist emailed Vascular Surgeon about it immediately - except he's on leave. But I *do* need an ENT for that glomus vagale tumour, even high end Endocrinologist said that an Endocrine surgeon would not be good enough / skilled enough for that glomus vagale tumour. You know what kind of tumour I don't recommend? The one that surgeons go: 'no I don't want to deal with that one I'll handle the other ones thanks.')

Secondly, *there are no specialists that deal with my condition in Western Australia.* None. Not a single one. Even Prof John Walsh (who I didn't see today) - while recommended - is not a specialist.

This meant that while I was seeing one of the best Endocrinologists in the state, I still knew more about my disease, condition, treatment options, recommendations, new research and so on than he did. Let's take a moment to think about how reassuring that felt. Glen's gonna run and get some Maltesers because this part of the film sucks.

In moderately good but entirely expected news, I'm getting an appointment for a full body MRI and it was confirmed that I'll be getting full body MRIs every two years for the rest of my life, with plasma metanephrines every year for the rest of my life. *thumbs up*  

In other news, if I want to see John Walsh - the only Endo that's been recommended even though he's not actually a specialist in this condition, I mostly have to see how my luck pans out in the next appt (Charles Gairdner do not let you pick your doctor). If I don't see him there, he has private appointments once a week in the morning, at the Keogh Institute (research).

I'm a bit frustrated at this point and mostly trying not to be. I know this is such a rare disease and these tumours are so rare that you do end up knowing more than a lot of medical staff. But I did hope for *one* specialist in Western Australia. Just one. Additionally, I was really hoping to learn more about the risks re: the surgery, all I am learning at this point is that there are definitely a lot of risks associated with that glomus vagale tumour, enough that specialists are like '....ehhhhh talk to the ENT about that one :/'

My follow up with Vascular Surgeon is on May 11th. Between now and then we're going to Melbourne for 10 days, to mostly take my mind off things. The tumours are staying pretty quiet and they're growing pretty slowly, but my PTSD / mental state has started wearing a bit, and I had my first lengthy anxiety attack the other night. Nothing I haven't dealt with before, I'd just hoped to put off that part of the process a bit longer.

So here we are, intermission is coming, and then we're back to watch the rest of the movie and the inevitably slide of Thelma and Louise into the abyss of surgical waste! Thanks for joining me, I'll see you next time! *noms on Maltesers.*

[not-poignant]

Tumour update time!

So this week I have some annoying pathology tests, and one of them is a 24 hour urine test (collect all urine over 24 hours - along with no exercise, no chocolate, no caffeine, no vanilla, no citrus, avoiding half my meds etc. and then on top of that ‘no stress’ which is hilarious because I find all of this rather stressful and I have Post-Traumatic Stress Disorder) and anyway, I was pretty frustrated at all of this.

(Because it’s not just the 24 hours, I have to fast tonight for the plasma version of this test tomorrow. And then the avoiding all the other shit starts from tomorrow into Friday morning).

But I told my brother, and he’s like ‘you have to pee non-stop for 24 hours???’

And I was like ‘...No. How does someone even do that?’

Him: ‘I thought they’d give you something to like make you pee for 24 hours without stopping.’

Me: ‘You know, you’ve done what no one else could do. You’ve made me grateful that I only have to collect and fridge all my pee over 24 hours. I’d die if I had to pee solidly for 24 hours.’

So there’s that. Thanks bro.

Also in other update-y type news, I have a meeting with the Endocrinology department at Charlies (er, Charles Gairdner Hospital) on the 18th. My MRI and CT results have come back in, and it’s all pretty much what the first CT scan showed, with better imagery. In good news, the glomus vagale paraganglioma isn’t feeding directly into the jugular and it hasn’t penetrated the tympanic membrane, but in bad news, it’s still in the vagus body of the vagus nerve. In general bad news, both tumours are absolutely packed with ‘arterial feeders’ probably means two surgeries over two days again :( (if they decide to take both out at the same time anyway. Last time they also needed to do an embolectomy on the first day, which is putting coils or embolisation material into the tumours to try and shut off their blood supply so I don’t bleed out the next day since they’re going to have their hands full worrying about hypertensive crisis...

Er, these tumours have a bad habit of occasionally secreting a metric fuckton of catecholamines when you touch them with a scalpel and creating a catecholamine ‘dump’ and then people die from that, as opposed to anything else. I’m not a fan of this disease tbh.)

Things are starting to get more serious now. Both in terms of getting a picture of what the risks are re: the surgery, but also knowing that I’m closer to getting this surgery. I have the head of Vascular, the head of Endocrinology, and possibly the head of ENT all collaborating. Good care. But you only get this kind of care in the public system when your situation sucks. In other good news, I’ve been triaged as an urgent patient in the public hospital system too, so things are happening pretty speedily. Hence the 24 hour fridge pee test this week. Fridge pee test!

Also for those who like really complicated details about diseases, I found this amazing resource on my disease here. I have the SDH/D variant, for anyone curious.

[littlenoobooplumbobs]

Rose’s house and greenhouse are starting off pretty small since I bought her a big lot.